4.7 Review

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

期刊

ANNALS OF ONCOLOGY
卷 27, 期 11, 页码 2004-2016

出版社

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw321

关键词

predictive biomarkers; NSCLC; platinum; antimetabolites; topoisomerase inhibitors; spindle poisons

类别

资金

  1. Etablissement Public Chancellerie des Universites de Paris (Legs Poix)
  2. Fondation de France [Engt 2013 00038309]
  3. Fondation ARC pour la Recherche sur le Cancer [PJA 20131200170]
  4. Agence National de la Recherche [ANR-10-IHBU-0001]
  5. Institut National du Cancer [INCa-DGOS-INSERM6043]

向作者/读者索取更多资源

Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell lung cancer (NSCLC) treatment since decades and still represents a key element of the therapeutic armamentarium. Contrary to molecularly targeted therapies and immune therapies, for which predictive biomarkers of activity have been actively looked for and developed in parallel to the drug development process ('companion biomarkers'), no patient selection biomarker is currently available for CCC, precluding customizing treatment. We reviewed preclinical and clinical studies that assessed potential predictive biomarkers of CCC used in NSCLC (platinum, antimetabolites, topoisomerase inhibitors, and spindle poisons). Biomarker evaluation method, analytical validity, and robustness are described and challenged for each biomarker. The best-validated predictive biomarkers for efficacy are currently ERCC1, RRM1, and TS for platinum agents, gemcitabine and pemetrexed, respectively. Other potential biomarkers include hENT1 for gemcitabine, class III beta-tubulin for spindle poisons, TOP2A expression and CEP17 duplication (mostly studied for predicting anthracyclines efficacy) whose applicability concerning etoposide would deserve further evaluation. However, none of these biomarkers has till now been validated prospectively in an appropriately designed and powered randomised trial, and none of them is currently ready for implementation in routine clinical practice. The search for predictive biomarkers to CCC has been proven challenging. If a plethora of biomarkers have been evaluated either in the preclinical or in the clinical setting, none of them is ready for clinical implementation yet. Considering that most mechanisms of resistance or sensitivity to CCC are multifactorial, a combinatorial approach might be relevant and further efforts are required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据